LONDON, June 7, 2010 /PRNewswire/ -- Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo (HR=0.46, p=0.0001). The results of the ZETA study were presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

ZETA was a phase III, randomised, double-blind, placebo-controlled, multi-centre study, evaluating oral once-daily vandetanib 300mg in 331 patients with unresectable, locally advanced or metastatic hereditary or sporadic medullary thyroid cancer and the presence of a measurable tumour. This was the first phase III trial with definitive results, carried out for patients with advanced MTC.

Significant differences for vandetanib compared to placebo were also observed in secondary endpoints of objective response rate and disease control rate--the response rate in patients receiving vandetanib was 45%. Patients receiving vandetanib also had a significant decrease in calcitonin and CEA biomarkers. Overall survival (OS) data at the time of presentation was immature.

The most common adverse events associated with vandetanib in this study, included rash, diarrhoea, hypertension, fatigue and headache (incidence 20% overall). The incidence of protocol-defined QTc prolongation was 8%. The safety profile of vandetanib in this study was similar to what has been previously observed in other studies in medullary thyroid and non small cell lung cancer.

Patients with advanced medullary thyroid cancer currently have few or no options for treatment once they reach this late stage of their disease, said Peter Langmuir, M.D. Executive Director, Medical-Science, AstraZeneca. Given the results of this trial, we are moving quickly to file regulatory submissions for approval with the FDA and the EMA.

Vandetanib 300mg has orphan drug designation in the US and Europe for the treatment of patients with advanced medullary thyroid cancer and AstraZeneca plans regulatory submissions in 2010. Vandetanib is thought to work by inhibition of the vascular endothelial growth factor (VEGF) pathway, epidermal growth factor receptor (EGFR) and rearranged during transfection (RET) pathways.

About Vandetanib

Vandetanib blocks the development of tumour blood supply by inhibition of the VEGF pathway, and by inhibiting the growth and survival of the tumour through EGFR and RET pathways.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:

This press release has been made available on worldwide press communication media for the benefit of correspondents writing for the medical professional press. Differing national legislation, codes of practice, medical practice etc mean that you should contact your local AZ press office to obtain information designed for use in your country.

SOURCE: AstraZeneca

CONTACT: For further information please contact: Global Media Inquiries:Ben Strutt, Global PR Director, AstraZeneca, Tel: +44(0)1625-230076, Mob:+44(0)7919-565990, Email: